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Abstract
Treatment with nitisinone (NTBC) has brought about a drastic improvement in the treatment and prognosis of hereditary tyrosinemia
type I (HT1). We conducted a retrospective observational multicentric study in Spanish HT1 patients treated with NTBC to assess
clinical and biochemical long-term evolution.
We evaluated 52 patients, 7 adults and 45 children, treated with NTBC considering: age at diagnosis, diagnosis by clinical
symptoms, or by newborn screening (NBS); phenotype (acute/subacute/chronic), mutational analysis; symptoms at diagnosis and
clinical course; biochemical markers; doses of NTBC; treatment adherence; anthropometric evolution; and neurocognitive outcome.
The average follow-up period was 6.1±4.9 and 10.6±5.4 years in patients with early and late diagnosis respectively. All patients
received NTBC from diagnosis with an average dose of 0.82mg/kg/d. All NBS-patients (n=8) were asymptomatic at diagnosis
except 1 case with acute liver failure, and all remain free of liver and renal disease in follow-up. Liver and renal affectation wasmarkedly
more frequent at diagnosis in patients with late diagnosis (P< .001 and .03, respectively), with ulterior positive hepatic and renal
course in 86.4% and 93.2% of no-NBS patients, although 1 patient with good metabolic control developed hepatocarcinoma.
Despite a satisfactory global nutritional evolution, 46.1% of patients showed overweight/obesity. Interestingly lower body mass
index was observed in patients with good dietary adherence (20.40±4.43 vs 24.30±6.10; P= .08) and those with good
pharmacological adherence (21.19±4.68 vs 28.58±213.79).
intellectual quotient was ≥85 in all NBS- and 68.75% of late diagnosis cases evaluated, 15% of which need pedagogical support,
and 6.8% (3/44) showed school failure.
Among the 12 variants identified in fumarylacetoacetate hydrolase gene, 1 of them novel (H63D), the most prevalent in Spanish
population is c.554–1 G>T.
After NTBC treatment a reduction in tyrosine and alpha-fetoprotein levels was observed in all the study groups, significant for
alpha-fetoprotein in no NBS-group (P= .03), especially in subacute/chronic forms (P= .018).
This series confirms that NTBC treatment had clearly improved the prognosis and quality of life of HT1 patients, but it also shows
frequent cognitive dysfunctions and learning difficulties in medium-term follow-up, and, in a novel way, a high percentage of
overweight/obesity.
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1. Introduction
Hereditary tyrosinemia type 1 (HT1, OMIM 276700) is a severe
autosomal recessive disorder due to deficiency of fumarylace-
toacetate hydrolase (FAH, EC 3.7.1.2), the last enzyme in
tyrosine (Tyr) degradation pathway. Due to this defect, toxic
metabolites including succinylacetone (SA), maleylacetoacetate,
and fumarylacetoacetate, are formed. These products cause
severe liver dysfunction, renal tubulopathy, porphyria like
syndrome, cardiomyopathy, and hepatocellular carcinoma
(HCC) early in life.[1,2] Acute (presenting before 6 months of
age), subacute (presenting between 6 and 12months) and chronic
(presenting after 1 year) forms of the disease have been
described.[1] The age at onset of symptoms broadly correlates
with severity.[3] The HT1 frequency worldwide is about 1 in
100,000 individuals, but a higher incidence is observed in some
regions such as Turkey, Quebec; and India.[4] The FAH gene has
been cloned and mapped in human chromosome 15q, and 100
FAH mutations have been reported so far.[4]
Neonatal mass screening is conducted in many countries
around theworld and is essential to guarantee early diagnosis and
treatment during the neonatal period. Tyr as a screening
parameter is not appropriate due to the high rate of false-
positive, related to transient neonatal tyrosinemia, and false-
negative results; SA is the screening parameter of choice.[5,6]
Until the early 1990s, the only strategies available to manage
the symptoms ofHT1were protein-restricted diets (usually low in
phenylalanine, methionine, and Tyr) and liver transplantation. In
1992, an alternative treatment, (2-(2-nitro-trifluoromethylben-
zoyl) 1, 3-cyclohexanedione, also known as nitisinone or NTBC,
was introduced.[7] This treatment inhibits the upstream enzyme
4-hydroxyphenylpyruvate dioxygenase, thereby preventing the
formation of the toxic metabolites fumarylacetoacetate and
succinylacetoacetate (Fig. 1). NTBC treatment strongly increases
plasma Tyr concentrations, so this therapy should be comple-
mentary to diet restricted in Tyr and its precursor phenylalanine
(Phe) and should not be administered alone.[8,9] Liver dysfunction
is now controlled in >90% of patients, and extrahepatic
manifestations have been abolished or greatly improved with
combined treatment.[10] It is essential an early start of NTBC
therapy to avoid sequelae; ideally in the neonatal period.[1,11,12]
Eye pain, eye itching/conjunctivitis, corneal crystals, and
Figure 1. Metabolic pathway of tyrosine. Fumarylacetoacetate hydrolase is the deficient enzyme in tyrosinemia type 1. NTBC inhibits the upstream enzyme 4-
hydroxyphenylpyruvate dioxygenase preventing the formation of the toxic metabolites fumarylacetoacetate and succinylacetoacetate. NTBC=nitisinone.
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thrombocytopenia are the most common side effects reported[6]
and are mostly related to high Tyr levels and reversible when Tyr
levels decrease by strict dietary adherence. The risk of HCC has
markedly diminished after the introduction of NTBC, although
its occurrence has been also described in some HT1 subjects
under NTBC therapy.[1,13,14] Neurocognitive deficits could also
represent a problem in long-term management.[2,15,16]
Few studies until now had assessed in wide series the evolution
of HT1 patients treated with NTBC.[6,11] The aim of this
multicentric study is to evaluate Spanish patients with HT1 in
treatment with nitisinone, including novels aspects, not previ-
ously studied, as nutritional assessment and anthropometric
parameters.
2. Methods
2.1. Study design
This is a retrospective observational multicentric study developed
in Spanish HT1 patients treated with NTBC. The study protocol
was approved by the local research ethics committee of each
Center. All HT1 patients who received treatment with NTBC
were considered eligible and were recruited after informed
consent had been obtained.
2.2. Population
Patients were recollected through a noninterventional post-
authorization safety study to evaluate long-term safety of NTBC
(Orfadin) treatment in standard clinical care. Data were covered
by the physicians responsible for these patients from 14 regions in
Spain. The contact was made through the Scientific Society of
Inborn Errors of Metabolism of Spain.
At diagnosis, the following parameters were evaluated: age and
year of diagnosis, sex, type of diagnosis (by clinical symptoms or
by newborn screening [NBS]), mutational analysis of the FAH
gene, phenotype (acute, subacute, or chronic attending to the
onset of symptoms: <6 months; 6–24 months or >24 months,
respectively), presence of clinical symptoms and/or biochemical
markers and/or imaging studies suggesting diagnosis (liver, renal,
haematological, cognitive, ophthalmologic status, and others).
Treatment was held according to Spanish Guidelines,[17] during
follow-up patients received not only NTBC treatment but also a
dietary restricted in Tyr and Phe, according to age and tolerance.
Clinical course was subsequently monitored. Follow-up included
start date of NTBC treatment and follow-up time; dose of NTBC
per kg administered; adherence to diet and pharmacological
treatment (good, regular, poor, and very poor); measurement of
SA, Phe, Tyr, alpha-fetoprotein (AFP) and NTBC blood
concentrations, SA in urine; assessment of anthropometric
parameters (weight, height, body mass index [BMI]); evolution
of clinical symptoms (liver, renal, haematological, cognitive,
ophthalmologic status, and others); development or not of HCC;
behavioral assessment (deficit or not of attention and hyperac-
tivity syndrome); schooling (normal or with support); intellectual
quotient (IQ) testing.
2.3. Methods
2.3.1. Anthropometric methods. Recumbent length was mea-
sured with a measuring board and weight with a manual baby
scale until the age of 24 months. Thereafter, standing height was
measured with a wall-mounted stadiometer and body weight, to
the nearest 100g, with digital scales. Patients were weighted
barefoot and after overnight fasting. Weight and height
percentiles and z-scores were calculated using the online
nutritional assessment tool of the Spanish Society of Gastroen-
terology, Hepatology, and Nutrition (www.gastroinf.es).
The nutritional status was performed by calculating the BMI as
BMI = weight (kg)/height2 (m2). Subjects were classified
according to BMI by using the WHO Child Growth Standards
(underweight: BMI percentile <15; normal: BMI percentile 15–
85, overweight: BMI percentile 85–95, obese: BMI percentile
>95).[18,19]
2.3.2. Analytical methods. NBS for HT1 by levels of Tyr (cut-
off level: 200mmol/L) and SA as the second marker or only SA on
filter paper blood spots using tandem mass spectrometry was
done in the regions of Spain where expanded NBS was first
performed (Galicia, Cataluña, Madrid, and Murcia).
Quantitative analysis of amino acids (Phe, Tyr) in plasma
samples was carried out by ion-exchange chromatography
(Biochrom 30 autoanalyzer) after deproteinization of the sample
(plasma or urine) with 5-sulfosalicylic acid. SA was detected in
dried blood spot by a kit of Chromsystems (Teknokroma,
Barcelona, Spain) by tandem mass spectrometry. AFP and some
other routine biochemical parameters were analyzed in the
respective laboratories associated with each center, but because
the reference ranges of these parameters are standardized, we
assumed that the slight variability among them is of no clinical
significance. NTBC concentrations were evaluated by using
tandem-mass spectrometry.[20]
Reference range values for biochemical parameters were: SA
(<0.1mmol/L in blood and<1mmol/mol creatinine in urine), Phe
(35–120mmol/L), Tyr (<400mmol/L), AFP (<10mg/L, in the first
year of life less than 77mg/L in girls and 22mg/L in boys), NTBC
(30–60mmol/L).
 Abdominal ultrasound and/or liver magnetic resonance
imaging, and ophthalmologic examination were also done in
each reference center according to the chronology indicated in
the Spanish follow-up protocol.
 Molecular testing: DNA was isolated and sequenced by
standard procedures for blood samples of all patients and
their parents. Molecular analysis of FAH was performed using
standard procedures. Primers were designed to overlap the
coding sequences and their flanking regions (sequences
available on request). Polymerase chain reaction products
were purified by ExoSap (usb) enzyme and sequenced using a
Big Dye Terminator Cycler Sequencing Ready reaction kit and
the manufacturer’s protocol (Applied Biosystems, Waltham,
Massachusetts). The sequencing reactions were performed in
an ABI 3130XL Genetic Analyser.
2.3.3. Cognitive function. Cognitive function was assessed by
psychomotor development index (PDI) or IQ using the Wechsler
intelligence scale R for school-age children, the McCarthy Scales
of Children’s Abilities for preschool-age children, and the
Brunet–Lèzine scale in infants. The overall index score of PDI
or IQ is considered in the normal range when it is above 85.
2.4. Statistical analysis
Datawere analyzed using the R statistical package v3.4.0 [RCore
Team (2017). R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Couce et al. Medicine (2019) 98:39 www.md-journal.com
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Austria. URL https://www.r-project.org/, last accessed: 12/07/
2018]. Sample normality was assessed using both the Kolmo-
gorov–Smirnov and the Shapiro–Wilk tests. In cases where one of
the variables was quantitative and the other qualitative, we
applied the Student t test if the quantitative variable was normally
distributed, and the Wilcoxon signed-rank test otherwise. Fisher
exact test or Chi-squared tests were used when both variables
were qualitative. To assess correlations between quantitative
variables, we used the Pearson correlation for normally
distributed data and the Spearman rho otherwise. The resulting
P-values were adjusted using the Bonferroni correction and only
values lower than .05 were considered significant.
3. Results
3.1. Diagnosis
We evaluated 52 Spanish patients, 7 adults and 45 children
(57.7% male; mean age: 11 years and 8 months, range: 2
months–24 years) with HT1. The characteristics of the study
population are detailed in Table 1. All patients receive treatment
with NTBC from diagnosis. Eight of them (p1–p8) were early
detected byNBS, all being asymptomatic except for 1 that already
had liver failure data at diagnosis. In 5 patients NBS was
performed using Tyr in blood spot as a primary marker and SA as
a secondary marker, and in the remaining 3 patients SA was the
primary marker. The average age for diagnosis was 12.7 days
(range 7–21).
A total of 44 (84.6%) of our patients were diagnosed at a later
stage due to by the appearance of clinical symptoms (no-NBS
group) (median age at diagnosis: 241 days, range: 22–1428)
with noteworthy delay in diagnosis respect with NBS cases
(P< .001). Acute presentation was the most frequent form (24/
44; 54.5%), followed by subacute presentation in 31.8% (14/
44) and chronic presentation in 13.6% (6/44). Liver affectation
was markedly more frequent at diagnosis in cases with late
diagnosis (43/44) compared to cases detected by NBS (1/8)
(P< .001). In acute forms, acute liver failure stands out as the
most frequent hepatic manifestation (75% – 18/24) followed by
hepatomegaly (25% – 6/24) and hepatic nodules (20.8% – 5/
24). In those patients with subacute/chronic form the incidence
of hepatomegaly, in 3 patients together with splenomegaly, and
hepatic nodules is greater (90% and 35%, respectively). In a
patient with a chronic form the debut was due to a
hepatoblastoma.
In no-NBS group kidney involvement at diagnosis was present
in 20/44 (45.4%), also more frequent than in NBS-group
(P= .03), including renal tubular dysfunction (17/44), nephro-
megaly (7/44), nephrocalcinosis (7/44), renal dysfunction (1/44),
and Fanconi syndrome (1/44, patient 14), with higher frequency
in acute forms of tubulopathy and nephrocalcinosis and in
subacute/chronic forms of nefromegaly. Hypophosphatemic
rickets was observed in 4 acute and 1 subacute patients, and 3
patients had neurological crises at diagnosis. Other manifes-
tations at diagnosis in no-NBS group were vomiting (18%),
hypoglycemia (15.9%), sepsis (9%), and growth failure (6.8%).
As reflected in Table 2, Tyr, AFP, and SA levels at diagnosis
were slightly lower in NBS-group than in those with late
diagnosis (Tyr: 416.7±153.5 vs 469.95±231mmol/L, P= .79;
AFP: 4.3 vs 5.9ng/mL, P= .84; and SA: 0.42 vs 0.5mmol/L,
P= .53). Both AFP and Tyr levels show a lineal correlation with
the time of evolution of the disease at diagnosis with higher levels
in chronic forms of tyrosinemia (P=0.048 for AFP). No relevant
differences were observed in Phe levels between the 2 groups.
3.2. Follow-up
The average follow-up period was 6.1±4.9 years in patients with
early diagnosis and 10.6±5.4 years in those with late diagnosis.
All patients received NTBC from diagnosis with an evolving
average dose of 0.82mg/kg/d (range: 0.44–1.34) according to
NTBC levels. A good diet adherence was observed in 87% of
NBS-patients and 65% of patients with late diagnosis, while only
1 patient showed poor adherence to pharmacological treatment.
General clinical outcome was positive in most patients; only 6
patients, all of them not diagnosed by NBS, developed hepatic
manifestations, in addition to the patient with hepatoblastoma at
diagnosis: hepatic nodules (3; cases number 32, 39, and 50),
hepatic hyperechogenicity (case number 40), hepatic cirrhosis
(case 50), and hepatic steatosis (case 45). Only 1 case of new
hepatic malignancy was observed in our series: a female patient
with a subacute form (case number 42), good dietetic and
therapeutic adherence, and Tyr and NTBC levels within range,
who developed a hepatocarcinoma at the age of 13 years and
needed liver transplantation. All NBS patients continued free of
liver and renal disease.
In no-NBS group renal evolution was satisfactory after
treatment in 41/44 patients, 1 patient developed renal dysfunc-
tion secondary to chemotherapy treatment of hepatoblastoma
and 2 maintained nephrocalcinosis. Hematological and ophthal-
mological evolution was good except in 1 patient, with very poor
diet and treatment adherence, who developed ocular manifes-
tations. Six patients, 5 of them with acute form and 1 with
subacute diagnosis, presented seizures: photosensitive epilepsy
(1/6), myoclonic epilepsy (2/6), absence crisis (1/6), and 2 with an
isolated seizure.
It highlights that anthropometric evolution is our series is
satisfactory as almost half of the HT1 patients maintained a BMI
adequate to their age and sex (47.06%). Only 3 patients, all of
them of late diagnosis, showed underweight in their follow-up,
nevertheless the percentage of obesity and overweight in our
study population is high, and interestingly, no significant
differences were observed in this percentage between NBS and
no-NBS groups. No patient has shown development of diabetes
or hyperglycemia so far.
We evaluate the correlation between BMI with several
variables: Tyr levels, duration of pharmacologic or dietetic
treatment, and adherence to both treatments, and we found a
significant correlation between BMI and NTBC treatment
(P-value: 9.62e05; rho=0.5987515). BMI was both lower in
patients with good dietary adherence (20.40±4.43 vs 24.30±
6.10; P= .08) and in those with good adherence to NTBC
treatment (21.19±4.68 vs 28.58±213.79).
Learning difficulties were not observed in NBS-patients but in
late-diagnosis group pedagogical support or curricular adapta-
tion was necessary in 15% of patients, and 6.8% (3/44) showed
school failure, 1 case with concomitant diagnosis of Angelman
syndrome and 2 with poor diet and pharmacological adherence.
Thirty-eight patients had cognitive evaluation. IQ was ≥85 in all
NBS- and 68.75%of late diagnosis cases evaluated; in this second
group, 3 patients with acute-onset and 1 with chronic
presentation, showed IQ 70. A negative correlation between
the duration of NTBC treatment and IQ was not verified in our
series by a logistic regression model. Seventeen percent of HT1
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patients showed attention hyperactivity and attention deficit and
no neurological crises were observed in the study cohort during
the follow-up period.
After treatment with NTBC a reduction in Tyr and AFP levels
was observed in all the study groups, significant for AFP in the
group with clinical diagnosis (P= .03) and specially in the
subacute/chronic forms (P= .018) (Fig. 2).
Genetic study was carried out in 36 patients and 12 different
variants in FAH gene were detected. All variants were previously
described,[26–31] except a novel variant (H63D) identified in
Figure 2. Comparison between tyrosine, succinylacetone and alpha-fetoprotein levels in the NBS, acute and subacute/chronic patients at diagnosis and in the
follow-up, after treatment with NTBC. NBS=neonatal screening, NTBC=nitisinone.
Table 2
Clinical, analytical, and anthropometric evolution of tyrosinemia type 1 Spanish patients.
Clinical diagnosis
n (%)
All sample
(n=52)
Newborn diagnosis
(NBS) (n=8) All (n=44) Acute (n=24)
Subacute or
chronic (n=20) P1 P2
Age at diagnosis, d 206 (7–1428) 13 (7–25) 241 (22–1428) 104 (22–370) 406 (33–1428) .0001 .0004
Clinical manifestations
Poor status at diagnosis
Hepatic 44 (84.6%) 1 (12.5%) 43 (97.7%) 23 (95.8%) 20 (100%) <.001 .36
Renal 20 (38.4%) 0 20 (45.4%) 11 (45.8%) 9 (45%) .03 .53
Hematological 16 (30.7%) 0 16 (36.3%) 8 (33.3%) 8 (40%) .01 .42
Ophthalmic 1 (1.9%) 0 1 (2.2%) 1 (4.2%) 0 .70 .32
Neurological 3 (5.7%) 0 3 (6.8%) 2 (8.3) 1 (5%) .73 .55
Poor status follow-up
Hepatic 6 (11.5%) 0 6 (15%) 1 (4.2%) 5 (25%) .06 .05
Renal 3 (5.7%) 0 3 (6.7%) 2 (8.3%) 1 (5%) .70 .55
Hematological 1 (1.9%) 0 1 (1.9%) 0 1 (5%) .34 .28
Ophthalmic 1 (1.9%) 0 1 (1.9%) 0 1 (5%) .40 .26
Neurological 6 (11.5%) 0 6 (15%) 0 1 (5%)
Analytical parameters
At diagnosis:
Succinilacetone, mmol/L 0.50 (0.37–0.70) 0.42 (0.37–0.80) 0.50 (0.30–0.75) 0.50 (0.40–0.75) 0.45 (0.30–0.91) .79 .71
Alpha-fetoprotein, mg/L 5.33 (3.10–8.60) 4.30 (3.25–7.65) 5.9 (3.05–9.5) 5.07 (2.30–6.95) 6.00 (3.85–13.6) .84 .05
Phenylalanine, mmol/L 44.57±15.02 42.46±16.53 46.90±14.33 46.90±14.33 42.62±15.68 .69 .35
Tyrosine, mmol/L 461.9±220.4 416.7±153.5 469.95±231 453.08±234.6 490.2±230.9 .53 .60
Follow-up:
Succinilacetone, mmol/L 0.43 (0.18–19) 0.40 (0.3–0.57) 0.60 (0.30–0.65) 0.60 (0.50–0.67) 0.42 (0.18–0.65) – .71
Alpha-fetoprotein, mg/L 4.64 (3.1–8.6) 2.6 (1.6–8.6) 2.36 (1.13–4.35) 3.05 (1.9–7.4) 1.90 (0.55–3.76) .91 .02
Tyrosine, mmol/L 408.4±161.1 393.1±121.5 427.29±151.9 413.1±183.1 437.2±135.7 .41 .99
Treatment
NTBC levels, mmol/L 36.51 (8–80) 38.06 (8–30) 39.81 (12–80) 41.95 (12–80) 37.25 (12–80) .76 .10
Diet compliance
Good 36 (69.23%) 7 (87.5%) 14 (58.33%) 15 (75%) .09 .13
Regular/poor 16 (30.76%) 1 (12.5%) 10 (41.6%) 5 (25%)
Anthropometric evolution
BMI
Normal 24 (47.06%) 4 (57.14%) 9 (37.5%) 11 (55%) .980 .770
Underweight 3 (5.88%) 0 3 (12.5%) 0
Overweight + obese 24 (46.15%) 3 (42.86%) 12 (50%) 9 (45%)
Cognitive status
PDI or IQ
Normal 38 (73.08%) 8 (100%) 30 (68.08%) 15 (62.5%) 15 (75%) .009 .51
Poor 14 (26.92%) 0 14 (31.82%) 9 (37.5%) 5 (25%)
Data expressed as mean, except for succinilacetone; alpha-fetoprotein; and NTBC levels, express as median and range in parentheses.
BMI=body mass index, IQ= intellectual quotient, NBS=newborn diagnosis, NTBC=nitisinone, PDI=psychomotor development index.
P1=newborn diagnosis versus clinical diagnosis, P2= acute versus subacute + chronic presentation.
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homozygosis in a male patient with a chronic form of HT1. The
most prevalent Spanish mutation is c.554–1 G>T (IVS6–1 G>T)
(63.89% – 23/36), 16 patients showed this mutation in
homozygosis (16/23 – 69.57%) and 7 in heterozygosis (7/23 –
30.43%) (Table 3). In the group of patients homozygous for
c.554–1 G>T, 93.8% had hepatic and 50% renal involvement at
diagnosis. The hepatic evolution of HT1 patients with the
aforementioned variant, considered together in both homo and
heterozygosis, is slightly worse when compared to patients with
other mutations (poor hepatic status in the follow-up: 12.5% vs
8.33%, respectively, P= .95). Moreover, the patient who
developed hepatocarcinoma is homozygous for this mutation.
Thus, the mutation c.554–1 G>T, despite the absence of
statistical significance with patients harboring other mutations,
probably due to the low sample size in mutational comparison
groups, seems to condition a worse hepatic prognosis even in
spite of the treatment. The comparison between the follow-up
according to the genotype is shown in Table 4.
4. Discussion
NTBC has brought about a drastic improvement in the treatment
and prognosis of HT1 as all the clinical multiorganic
complications associated to toxic metabolites accumulation in
this pathology have been shown to be preventable with NTBC
therapy.[6,11,21] Evidence supported that earlier treatment with
NTBC and dietary protein restriction within the first 2 months of
life showed a lower rate of complications (hepatic and renal
dysfunction)[12]; shorter hospital admissions and a reduced need
for liver transplantation.[22] In accordance with previous series of
HT1,[6,11,21,23] our revision confirms a clear clinical benefit with
the combination of NTBC and dietary treatment. From the 43
patients with hepatic affectation at diagnosis (1 NBS-patient, 23
with acute onset and 19 with subacute-chronic presentation) only
6 maintain hepatic damage in the follow-up. In The Québec
NTBC study no patient with early treatment (before 1 month of
age) had developed to date HCC; in our series, with a long-follow
up period (up to 15 years in some patients), but shorter than the
surveillance of the referred study (up to 20 years), a new hepatic
malignancy was observed in the follow-up in a patient diagnosed
at about 1 year of age who maintained a good metabolic control.
As signaled by Geppert et al systematic review,[22] any of our
patients developed renal dysfunction after NTBC treatment and,
moreover, renal outcome of those HT1 patients with renal
pretreatment involvement was meanly satisfactory.
A good metabolic control, judged by normalization of plasma
SA and Tyr levels, was achieved quickly in treated patients. In our
series, the greatest effect in reducing AFP levels was observed in
no-NBS group, especially in those patients with subacute/chronic
forms (Fig. 1).
Table 3
Molecular study of the Spanish HT1 patients.
Percentage
Variant Number of cases (n=36) Number of alleles (n=71) Heterozygosis Homozygosis
c.554–1G>T 23 (63.89%) 39 (54.9%) 7 (30.43%) 16 (69.57%)
c.1062+5G>A 10 (27.78%) 14 (19.7%) 6 (60%) 4 (40%)
c.982C>T 3 (8.33%) 4 (5.6%) 2 (66.67%) 1 (33.33%)
c.782C>T 2 (5.56%) 4 (5.6%) 0 (0%) 2 (100%)
c.398A>T 1 (2.78%) 2 (2.8%) 0 (0%) 1 (100%)
938delC 1 (2.78%) 1 (1.4%) 1 (100%) 0 (0%)
c.1027G>T 1 (2.78%) 1 (1.4%) 1 (100%) 0 (0%)
c.233G>A 1 (2.78%) 1 (1.4%) 1 (100%) 0 (0%)
c.974C>T 1 (2.78%) 1 (1.4%) 1 (100%) 0 (0%)
c.836A>G 1 (2.78%) 1 (1.4%) 1 (100%) 0 (0%)
c.913G>C 1 (2.78%) 1 (1.4%) 1 (100%) 0 (0%)
H63D 1 (2.78%) 2 (2.8%) 0 1 (100%)
Percentages were calculated with respect to the 36 patients in whom the genetic study was carried out.
HT1=hereditary tyrosinemia type I.
Table 4
Comparison between hepatic and renal evolution according to the genotype.
Hepatic evolution
All patients (n=52)
Patients with molecular
study (n=36)
Patients homozygous for
c.554-1 G>T (n=16)
Patients with other
variant (n=12) P
Good status 46 (88.46%) Good status 32 (88.89%) Good status 14 (87.5%) Good status 11 (91.67%) .95
Poor status 6 (11.54%) Poor status 4 (11.11%) Poor status 2 (12.5%) Poor status 1 (8.33%)
Renal evolution
All patients (n=52)
Patients with molecular
study (n=36)
Patients homozygous
for c.554-1 G>T (n=16)
Patients with other
variant (n=12) p
Good status 49 (94.23%) Good status 34 (94.44%) Good status 16 (100%) Good status 11 (91.67%) .85
Poor status 3 (5.77%) Poor status 2 (5.56%) Poor status 0 (0%) Poor status 1 (8.33%)
The comparison between patients with c.554-1 G>T in homozygosis versus those with other variant was made by the Fisher test with Benjamini–Hochberg correction.
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Actually, despite this good metabolic response, a main concern
in HT1 treatment is the high frequency of neurocognitive
impairment of HT1 patients showing a lower IQ, impaired
executive functioning, motor abilities, and social cognition and
schooling problems.[2,15,16] The exact pathophysiological mech-
anisms underlying these impairments were not well elucidat-
ed.[24] Despite that no significant correlation between Tyr or Phe
plasma levels and IQ at school age was found in a recent study,[25]
a relation with chronic hypertyrosinemia has been suggested and
some clinical reports seemed to support this hypothesis.[23,26]
Our series showed a clearly better neurocognitive outcome in
NBS-patients with early treatment. Learning difficulties were
only observed in 23% of late-diagnosis patients The finding of
frequent attention hyperactivity and attention deficit (17%) is
consistent with the results reported in other studies[27] and less of
10%ofHT1 patients presented seizures, percentage similar to the
observed in an European cross-sectional study.[6]
It is remarkable in our series that QI in the follow-up remains
within a normal range in all the NBS-patients evaluated and in
73% of those with clinical diagnosis and only 4 patients from the
38 with QI assessment showedQI<70. This results contrast with
those reported previously with a high number of patients with
intellectual and psychomotor delay.[15,21,25]
Although the observation of a negative correlation between the
duration of treatment with NTBC and IQ,[2] a recent animal
model showed that this slower learning and cognitive impairment
is caused by HT1 and not by NTBC treatment itself.[28] Our
results endorse it, as no significant relation was demonstrated by
a logistic regression model between the duration of NTBC
treatment and IQ. Neither correlation was objectified between IQ
and Phe/Tyr quotient (Spearman rho: 0.11; P-value: .57).
Although the low number of patients with poor dietetic-
therapeutic adherence prevents an adequate statistical compari-
son, the mean BMI is clearly lower in those patients with good
treatment compliance, which does not suggest that overweight/
obesity is related to the use of special formulas free of Tyr and
phenylalanine, which contrasts with studies carried out on other
inborn errors of amino acid metabolism as phenylketonuria.[30]
The most prevalent mutation in our cohort, c.554–1 G>T
(IVS6–1 G>T), is a splice mutation with higher prevalence in
Southern Europe and in Mediterranean region, previously
reported in other studies of Spanish HT1 patients,[10,29,31] and
ranks second in prevalence in European HT1 patients.[4] The
second mutation in frequency was c.1062+5 G>A [IVS 12+5
(G->A)], also a splice mutation previously described in our
country.[10,31,32] Both mutations together accounts for 74.6% of
the FAH alleles investigated (c.554–1 G>T: 39 alleles and c.1062
+5 G>A: 14 alleles). The rest of mutations are rare in our
population: c.982C>T,[30] c.836A>G,[31] c.233G>A,[31]
c.974C>T[10] and 1 of them (c.782C>T) was identified for the
first time in Spanish HT1 patients. This mutation, c.782C>T,
was found in 2 Caucasians patients from Madrid is a missense
mutation found in 100% of Ashkenazi-Jewish patients examined
in Israel[33] and also described in Saudi Arabia and Egypt.[34]
The main limitations of our study are the small number of NBS
patients included, reflecting that HT1 screening is not included in
the neonatal screening of most regions of our country which
results in a limitation of the statistical power of some
comparisons as well as the fact that the mutational study was
not performed in the entire population studied.
This series confirms that NTBC treatment had clearly improved
the vital prognosis and quality of life of HT1 patients, but it also
reveals cognitivemanifestations and learning difficulties amedium
term in a considerable number of patients, as well as, in a novel
way, a high percentage of overweight/obesity in HT1 patients.
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